Clinical Trials
6
Active:0
Completed:0
Trial Phases
3 Phases
Phase 1:3
Phase 2:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 2
2 (33.3%)Not Applicable
1 (16.7%)Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory
Not Applicable
- Conditions
- Early Stage Breast Cancer (Stage 0-III)
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT01157130
- Locations
- 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Phase 2
Withdrawn
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT01131247
- Locations
- 🇺🇸
Mayo Clinic, PHoenix/Scottsdale, Arizona, United States
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
Phase 2
Terminated
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT01125787
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Nevada Cancer Institute, Las Vegas, Nevada, United States
5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00886457
- Locations
- 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Nevada Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00880867
- Locations
- 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States
- Prev
- 1
- 2
- Next
News
No news found